A Review of Sildenafil in the Treatment of Pediatric Pulmonary Arterial Hypertension

被引:0
|
作者
Krishnan, Usha [1 ]
Lovig, Leif [1 ]
机构
[1] NY Med Coll, Dept Pediat, Valhalla, NY 10595 USA
关键词
sildenafil; pulmonary hypertension; endothelium; children; neonatal;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This is a review article that discusses the role of sildenafil in pediatric pulmonary hypertension. The etiopathogenesis as well as prognosis for pediatric pulmonary hypertension (PH) differs from adults. The basic tenets of targeted management of PH however are similar. Sildenafil and other phosphodiesterase-5 inhibitors play a very important role in PH management, especially because of the ease of administration, low adverse effect profile, better tolerability and relative cost effectiveness. This is especially vital in situations where inhaled nitric oxide is not easily available and fills an important therapeutic gap. Large double blinded and controlled studies studying the effects of sildenafil in pediatric PH are not available. Equally vital would be long term efficacy studies, which should be initiated through large multicenter trials, to study the beneficial as well as long term side effects of this medication in the pediatric age group.
引用
收藏
页码:1329 / 1333
页数:5
相关论文
共 50 条
  • [31] Sildenafil in the treatment of pulmonary hypertension
    Barnett, Christopher F.
    Machado, Roberto F.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (04) : 411 - 422
  • [32] Sildenafil citrate therapy for pulmonary arterial hypertension
    Izbicki, G
    Rosengarten, D
    Picard, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10): : 1091 - 1092
  • [33] Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension
    Hugo Juárez Olguín
    Hector Osnaya Martínez
    Carmen Flores Pérez
    Blanca Ramírez Mendiola
    Liliana Rivera Espinosa
    Juan Luis Chávez Pacheco
    Janett Flores Pérez
    Ignacio Mora Magaña
    World Journal of Pediatrics, 2017, 13 : 588 - 592
  • [34] Sildenafil citrate therapy for pulmonary arterial hypertension
    Galiè, N
    Ghofrani, HA
    Torbicki, A
    Barst, RJ
    Rubin, LJ
    Badesch, D
    Fleming, T
    Parpia, T
    Burgess, G
    Branzi, A
    Grimminger, F
    Kurzyna, M
    Simonneau, G
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20): : 2148 - 2157
  • [35] Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension
    Juarez Olguin, Hugo
    Osnaya Martinez, Hector
    Flores Perez, Carmen
    Ramirez Mendiola, Blanca
    Rivera Espinosa, Liliana
    Chavez Pacheco, Juan Luis
    Flores Perez, Janett
    Mora Magana, Ignacio
    WORLD JOURNAL OF PEDIATRICS, 2017, 13 (06) : 588 - 592
  • [36] CLINICAL EFFECTIVENESS OF BOSENTAN, EPOPROSTENOL, ILOPROST, SILDENAFIL AND TREPROSTINIL IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION A SYSTEMATIC REVIEW
    Becla, L.
    Osiska, B.
    Malottki, K.
    Lipska, I
    VALUE IN HEALTH, 2008, 11 (06) : A382 - A383
  • [37] POPULATION PHARMACOKINETICS MODEL AND PEDIATRIC DOSE RECOMMENDATION FOR IV SILDENAFIL IN PULMONARY ARTERIAL HYPERTENSION
    Hazra, A.
    Gao, X.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S87 - S88
  • [38] Identification Of Treatment Targets In Pediatric Pulmonary Arterial Hypertension
    Ploegstra, M. -J.
    Douwes, M.
    Roofthooft, M.
    Zijlstra, W. M. H.
    Hillege, H. L.
    Berger, R. M. F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [39] Sildenafil therapy in complex pulmonary atresia with pulmonary arterial hypertension
    Lim, Zek S.
    Vettukattill, Joseph J.
    Salmon, Anthony P.
    Veldtman, Gruschen R.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 129 (03) : 339 - 343
  • [40] Sildenafil and tadalafil: A new option in the treatment of patients with pulmonary arterial hypertension.
    Konorza, T
    Haude, M
    Katz, M
    Neudorf, U
    Erbel, R
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (6A): : 193E - 193E